Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Bluebird bio has made the decision to go private in order to restructure and focus on long-term growth amidst declining valuations and funding challenges in the biotech industry. This move reflects a strategic shift in response to the current market conditions. Johnson & Johnson continues to face legal battles over talc products, with a pending ruling that could potentially resolve the issue. This ongoing litigation highlights the importance of product safety and regulatory compliance in the pharmaceutical industry. In other news, Viking has secured a supply of an obesity pill candidate, demonstrating a commitment to addressing unmet medical needs in the field of obesity treatment. Roche has also made a significant play in the obesity market with a potential $5.3 billion pact, signaling confidence in the potential of this therapeutic area. The COVID-19 pandemic has had lasting impacts on the life sciences sector, prompting companies to adapt and innovate in response to changing market dynamics. The industry continues to evolve in light of these challenges, driving progress and innovation in healthcare. Overall, these developments underscore the dynamic nature of the pharmaceutical and biotech industries, highlighting the importance of strategic decision-making and adaptability in a rapidly changing landscape.